NKTX Projected Dividend Yield

Nkarta Inc ( NASDAQ : NKTX )

Nkarta is a biopharmaceutical company focused on the discovery, development and commercialization of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies to treat cancer. Co. has two product candidates, NKX101 and NKX019. Both product candidates were generated using Co.'s NK cell engineering platform. NKX101 is designed to improve the power of innate NK biology to detect and kill cancerous cells. NKX019 is based on the ability to treat a variety of B-cell malignancies by targeting the CD19 antigen that is found on these types of cancerous cells, where CD19-targeted engineered NK cells, T cells and monoclonal antibodies have demonstrated clinical activity.

20 YEAR PERFORMANCE RESULTS